Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

NCT ID: NCT02537691

Last Updated: 2019-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

483 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-28

Study Completion Date

2017-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, single-arm, longitudinal, international, multicenter study in a real-world cohort of adult severe asthma participants being conducted to assess the relationships between asthma biomarkers and asthma-related health-outcomes for a period of 52 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inhaled Corticosteroids (ICS) + Controller Medications

Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of \>/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.

Group Type OTHER

FP

Intervention Type DRUG

ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.

LABA

Intervention Type DRUG

LABA will be administered as per investigator discretion.

LTRA

Intervention Type DRUG

LTRA will be administered as per investigator discretion.

LAMA

Intervention Type DRUG

LAMA will be administered as per investigator discretion.

Theophylline

Intervention Type DRUG

Theophylline will be administered as per investigator discretion.

Oral Corticosteroids

Intervention Type DRUG

Oral corticosteroids will be administered as per investigator discretion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FP

ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.

Intervention Type DRUG

LABA

LABA will be administered as per investigator discretion.

Intervention Type DRUG

LTRA

LTRA will be administered as per investigator discretion.

Intervention Type DRUG

LAMA

LAMA will be administered as per investigator discretion.

Intervention Type DRUG

Theophylline

Theophylline will be administered as per investigator discretion.

Intervention Type DRUG

Oral Corticosteroids

Oral corticosteroids will be administered as per investigator discretion.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asthma diagnosed by a respiratory physician greater than or equal to (\>/=) 12 months prior to study enrolment
* Pre-bronchodilator FEV1 of 30 percent (%) to 85% at baseline/Visit 1
* Documented bronchodilator response defined as \>/=12% relative improvement in FEV1 after bronchodilator administration or a positive methacholine bronchial challenge test with provocative concentration causing a 20% fall in FEV1 (PC20) less than (\<) 8 milligrams (mg) at study baseline/Visit 1 or within 24 months prior to baseline
* Current treatment with a total daily dose of \>/= 500 micrograms (mcg) of fluticasone propionate (FP) dry powder inhaler (DPI) (or equivalent ) and at least one of the following controller medications: long-acting Beta-agonist (LABA), leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonists (LAMAs), theophylline or oral corticosteroids, with a continued duration of three months prior to baseline/Visit 1

Exclusion Criteria

* Acute or chronic parasitic, bacterial, fungal or viral infections that required, or currently require, hospitalization or antimicrobial treatment during the last four weeks prior to participant eligibility
* Acute asthma exacerbation or any other medical event treated with increased doses of oral, or any dose of intramuscular (IM) or intravenous (IV) corticosteroids within six weeks prior to study
* Other relevant pulmonary diseases (e.g. chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis) requiring treatment within 12 months prior to baseline/Visit 1
* Ex-smokers with \>/=10 pack-year smoking history
* Prior treatment with bronchial thermoplasty
* Participation in any clinical trial of an investigational agent or procedure within six months prior to baseline/Visit 1 or during the study
* Pregnancy prior to participation or during the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Center of Alabama, LLC

Birmingham, Alabama, United States

Site Status

Southern California Research Center

Mission Viejo, California, United States

Site Status

Capital Allergy Resp Dis Ctr

Sacramento, California, United States

Site Status

Allergy Assoc Medical Group

San Diego, California, United States

Site Status

Yale New Haven Hospital

New Haven, Connecticut, United States

Site Status

Waterbury Pulmonary Associates

Waterbury, Connecticut, United States

Site Status

AAADRS; Clinical Research Center

Coral Gables, Florida, United States

Site Status

Volunteer Medical Research

Port Charlotte, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

Georgia Pollens Clinical Research Centers

Albany, Georgia, United States

Site Status

Asthma & Allergy Center, P.C.

Papillion, Nebraska, United States

Site Status

Allergy & Asthma Research of Nj, Inc

Mount Laurel, New Jersey, United States

Site Status

Island Medical Research Pc

Commack, New York, United States

Site Status

Winthrop University Hospital

Mineola, New York, United States

Site Status

Laura and ISAAC Perlmutter Cancer Center at NYU Langone.

New York, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Vital Prospects Clin Res Pc

Tulsa, Oklahoma, United States

Site Status

Allergy-Asthma Specialists PC

Blue Bell, Pennsylvania, United States

Site Status

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Allergy & Clinical Immun Assoc

Pittsburgh, Pennsylvania, United States

Site Status

Berks-Schuylkill Respiratory Specialists, Ltd

Wyomissing, Pennsylvania, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Allergy & Asthma Res Ctr PA

San Antonio, Texas, United States

Site Status

Allergy Associates of Utah

Murray, Utah, United States

Site Status

Bridgerland Clinical Research

North Logan, Utah, United States

Site Status

Northridge Internal Medicine

Charlottesville, Virginia, United States

Site Status

O & O Alpan, LLC

Fairfax, Virginia, United States

Site Status

ASTHMA, Inc

Seattle, Washington, United States

Site Status

Pulmonary & Sleep Research

Spokane, Washington, United States

Site Status

Hospital Erasme; Neurologie

Brussels, , Belgium

Site Status

Private Practice

Jambes, , Belgium

Site Status

UZ Leuven Gasthuisberg

Leuven, , Belgium

Site Status

CHU Sart-Tilman

Liège, , Belgium

Site Status

CHU UCL Mont-Godinne

Mont-godinne, , Belgium

Site Status

Mhat - Pleven; Clinic of Pulmonology

Pleven, , Bulgaria

Site Status

Specialized Hospital for Active Treatment for pneumo-phtysiatric diseases

Rousse, , Bulgaria

Site Status

Vancouver General Hosp; The Lung Centre

Vancouver, British Columbia, Canada

Site Status

St. Paul's Hospital University of British Colambia Division of Hematology

Vancouver, British Columbia, Canada

Site Status

Burlington Lung Clinic

Burlington, Ontario, Canada

Site Status

Kingston General Hospital

Kingston, Ontario, Canada

Site Status

Inspiration Research Limited

Toronto, Ontario, Canada

Site Status

Centre Hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, Canada

Site Status

Jewish General Hospital; Endoscopy Department

Montreal, Quebec, Canada

Site Status

Hopital Laval; Centre de Pneumologie

Québec, , Canada

Site Status

Hvidovre Hospital, Lungemedicinsk Afdeling

Hvidovre, , Denmark

Site Status

Lungemedicinsk afd. L, Bispebjerg Hospital

København NV, , Denmark

Site Status

Hopital Bichat Claude Bernard ; Service de Pneumologie

Paris, , France

Site Status

Institut für Allergie- und Asthmaforschung Berlin, IAAB

Berlin, , Germany

Site Status

Berufsgenossenschaftliches Uni-Klinikum Bergmannsheil GmbH

Bochum, , Germany

Site Status

Lungenzentrum Darmstadt

Darmstadt, , Germany

Site Status

Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie

Essen, , Germany

Site Status

Universitätsklinikum Freiburg, Abteilung Pneumologie

Freiburg im Breisgau, , Germany

Site Status

Pneumologicum

Hanover, , Germany

Site Status

KPPK Studienzentrum GmbH; Dr. med. A. Kroker, Dr. med. O. Schmidt

Koblenz, , Germany

Site Status

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Medizinische Klinik, Pneumologie

Mainz, , Germany

Site Status

Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V

München, , Germany

Site Status

Dr. Kenessey Albert Korhaz Es Rendelointezet; Tudoosztaly (Pulmonolgy Dept )

Balassagyarmat, , Hungary

Site Status

Synexus Magyarorszag Kft

Budapest, , Hungary

Site Status

Szent János Kórház; Tüdőgondozó Intézet és Szűrőállomás

Budapest, , Hungary

Site Status

Debrecen Uni Medical School; Dept of Pulmonary Medicine

Debrecen, , Hungary

Site Status

Matrai Állami Gyógyintézet ; Bronchológia

Mátraháza, , Hungary

Site Status

Presidio Ospedaliero SS. Annunziata di Chieti ; Dip. Medico-UOSD Allergologia

Chieti, Abruzzo, Italy

Site Status

Policlinico di Modena; Oncologia, Ematologia e Patologie dell'apparato Respiratorio

Modena, Emilia-Romagna, Italy

Site Status

IRCCS AOU SAN MARTINO - IST;UO ALLERGOLOGIA-IMMUNOPATOLOGIA RESPIRATORIA e TERAPIE BIOTECNOLOGICHE

Genoa, Liguria, Italy

Site Status

AOU Città della Salute e della Scienza di Torino - Ospedale Le Molinette; SC Pneumologia

Turin, Piedmont, Italy

Site Status

Azienda Policlinico Vittorio Emanuele; Pneumologia Riabilitativa E Allergologia

Catania, Sicily, Italy

Site Status

A.O. Ospedali Riuniti; Villa Sofia-Cervello di Palermo; U. O. Pneumologia 2 - Padiglione B

Palermo, Sicily, Italy

Site Status

A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii

Pisa, Tuscany, Italy

Site Status

Clinical Hospital Gailezers; Dept of Pulmonology

Riga, , Latvia

Site Status

Riga 1st hospital, outpatient clinic Bruninieks

Riga, , Latvia

Site Status

Latvian University postgraduate institute

Riga, , Latvia

Site Status

Spaarne Ziekenhuis Hoofddorp; Long Geneeskunde

Hoofddorp, , Netherlands

Site Status

Medisch Centrum Leeuwarden; Longziekten

Leeuwarden, , Netherlands

Site Status

St. Antonius; R&D Long

Nieuwegein, , Netherlands

Site Status

CHVNG/E_Unidade 1; Servico de Pneumologia

Vila Nova de Gaia, , Portugal

Site Status

Research Institute of Complex Cardiovascular Pathology

Kemerovo, , Russia

Site Status

SBIH "Clinical dermatovenerologic dispensary " of Ministry of Health of the Krasnodar region

Krasnodar, , Russia

Site Status

FSBI "National Research Center - Institute of Immunology" of FMBA of Russia

Moscow, , Russia

Site Status

SBEI APE Russian Medical Academy of Post-graduate Education; Department of Clinical Allergology

Moscow, , Russia

Site Status

SBHI of NN region "RCH of NN n.a. N.A.Semashko"

Nizhny Novgorod, , Russia

Site Status

City Hospital #40 of Resort Administrative District

Saint Petersburg, , Russia

Site Status

City Out-patient Clinic #106

Saint Petersburg, , Russia

Site Status

Saratov State Medical University; Chair Of Clinical Allergology

Saratov, , Russia

Site Status

SBEI HPE "North Ossetian State Medical Academy" of Ministry of Health of Russia

Vladikavkaz, , Russia

Site Status

Complexo Hospitalario Universitario de Santiago

Santiago de Compostela, LA Coruña, Spain

Site Status

Hospital Universitario Puerta de Hierro Majadahonda; Servicio de Neumología

Majadahonda, Madrid, Spain

Site Status

Hospital de Galdakano; Servicio de Neumologia

Galdakano, Vizcaya, Spain

Site Status

Fundacio Santa Creu I Sant Pau

Barcelona, , Spain

Site Status

Hospital Clinic I provincial; Servicio de Neumologia

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofia; Servicio de Neumología

Córdoba, , Spain

Site Status

Hospital Universitario 12 de Octubre; Servicio de Neumologia

Madrid, , Spain

Site Status

Queen Elizabeth Hospital

Birmingham, , United Kingdom

Site Status

Bradford Royal Infirmary

Bradford, , United Kingdom

Site Status

Gloucestershire Royal Hospital

Gloucester, , United Kingdom

Site Status

William Harvey Research Institute

London, , United Kingdom

Site Status

St George's Hospital

London, , United Kingdom

Site Status

North Manchester Hospital; Respiratory Department

Manchester, , United Kingdom

Site Status

Freeman Hospital; Respiratory Department; Sir William Leach Lung Research Centre

Newcastle upon Tyne, , United Kingdom

Site Status

Queen Alexandra Hospital, Portsmouth

Portsmouth, , United Kingdom

Site Status

Royal Shrewsbury Hospital

Shrewsbury, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Bulgaria Canada Denmark France Germany Hungary Italy Latvia Netherlands Portugal Russia Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-000742-35

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MB29599

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Asthma Biomarker Study
NCT02392481 COMPLETED